Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Con...
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: GlobeNewswire
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formulation for the treatment of certain urea cycle disorders CELEBRATION, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an upcoming oral presentation at the International Niemann-Pick Disease Alliance (INPDA) Face-to-Face Meeting and several poster presentations at the Child Neurology Society (CNS) Annual Meeting, which will be reviewing clinical data on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) and OLPRUVA® (sodium phenylbutyrate) for t
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics announces CFO transition [Seeking Alpha]Seeking Alpha
- Zevra Therapeutics, Inc. Announces CFO TransitionGlobeNewswire
- Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/2/25 - Form 8-K
- 11/20/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- ZVRA's page on the SEC website